Methods and compositions for live attenuated viruses
AssigneeInviragen, Inc.
InventorsDan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
Life of this patent
Estimating the term…
Abstract
Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
Claims30
A live attenuated virus composition comprising:
- one or more live, attenuated viruses;
- one or more poly(ethylene oxide) and poly(propylene oxide) (EO-PO) block copolymers, the one or more EO-PO block copolymers include poloxamer 407,
- one or more proteins agents, the one or more protein agents include one or more albumins selected from the group consisting of lactalbumins and serum albumins, and
- one or more carbohydrate agents, the one or more carbohydrate agents include trehalose, wherein the composition is capable of reducing the inactivation of the live attenuated virus.
A method for decreasing inactivation of a live, attenuated virus composition comprising, combining one or more live attenuated viruses with a composition comprising one or more EO-PO block copolymers, the EO-PO block copolymers include poloxamer 407, one or more proteins agents, the one or more protein agents include one or more albumins selected from the group consisting of lactalbumins and serum albumins;
- and
- one or more carbohydrate agents, the one or more carbohydrate agents include trehalose, wherein the composition is capable of reducing inactivation of the live, attenuated virus.
A kit for decreasing the inactivation of a live, attenuated virus composition comprising:
- at least one container;
- and
- a composition comprising one or more albumins, the one or more albumins selected from the group consisting of lactalbumins and serum albumins, one or more carbohydrate agents, the one or more carbohydrate agents include trehalose, and one or more EO-PO block copolymers, the EO-PO block copolymers include poloxamer 407.
A live attenuated virus composition comprising:
- one or more live, attenuated viruses;
- one or more EO-PO block co-polymers including poloxamer 407;
- having a concentration of 0.1 to 4% (w/v);
- one or more albumins, the one or more albumins selected from the group consisting of lactalbumins and serum albumins;
- having a concentration from 0.001 to 3% (w/v) and
- one or more carbohydrate agents, the one or more carbohydrate agent include trehalose, wherein the composition is capable of reducing the inactivation of the live attenuated virus and wherein the composition is in aqueous form.
Dependencies are inferred from the claim text.